What changed
Late clinical-stage biotech pioneering SIRP-targeting precision meds for immune diseases and cancer. Lead candidate ipsoprubart is in a global registrational program for sHLH.
Use of proceeds: push ipsoprubart through its Phase 2/3 sHLH trial to topline data, prep for BLA submission and commercial launch. Also funding a Phase 1 in T/NK malignancies and ELA822 through Phase 1/2 in T cell-driven immune disorders.
Key risks: no approved products, zero revenue, and deep operating losses since inception. They’ll need substantial additional capital, and every candidate still faces failure on efficacy, safety, or regulatory grounds.
Bottom line: a pivotal-stage SIRP play with regulatory tailwinds and a clear path to data. Classic biotech IPO bet — binary, cash-hungry, but clinically de-risked enough to fit what 2025 buyers rewarded.
← Dashboard
Aug 28, 2026 08:06 PM ET